158 related articles for article (PubMed ID: 9838908)
1. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
Noda K; Tanaka K; Ozaki M; Hirabayasi K; Hasegawa K; Nishiya I; Yakushiji M; Izumi R; Tomoda Y; Ogita Y; Sugimori H; Yamabe T; Kudo R; Yajima A; Terashima Y; Fujii S; Suzuoki Y; Okada H; Kono I; Ochiai K; Yamamoto T; Ikeda M; Umesaki N; Saito T; Niitani H
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2061-8. PubMed ID: 9838908
[TBL] [Abstract][Full Text] [Related]
2. [Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
Ikeda M; Noda K; Hiura M; Tamaya T; Ozaki M; Hatae M; Ozawa M; Yamabe T; Tanaka K; Izumi R; Okada H; Ogita Y; Hoshiai H
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2249-57. PubMed ID: 9881082
[TBL] [Abstract][Full Text] [Related]
3. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
[TBL] [Abstract][Full Text] [Related]
4. [Phase I clinical study of 21-consecutive-day oral administration of etoposide].
Noda K; Fukuoka M; Komatsu H; Hayashihara K; Ariyoshi Y; Tanaka K; Nakajima H; Terashima Y; Nagao K; Furuse K
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1633-9. PubMed ID: 8060139
[TBL] [Abstract][Full Text] [Related]
5. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
7. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Rose PG; Markman M; Bell JG; Fusco NL
Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
[TBL] [Abstract][Full Text] [Related]
8. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus].
Noda K; Ikeda M; Yakushiji M; Nishimura H; Terashima Y; Sasaki H; Hata T; Kuramoto H; Tanaka K; Takahashi T
Gan To Kagaku Ryoho; 1992 Jun; 19(6):885-92. PubMed ID: 1605666
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
[TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Kim HS; Kang SB; Seo SS; Han SS; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():627-34. PubMed ID: 19723113
[TBL] [Abstract][Full Text] [Related]
11. [A phase II study of NK171 (etoposide)].
Kimura K; Niitani H
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
[TBL] [Abstract][Full Text] [Related]
12. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
13. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
14. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
15. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
[TBL] [Abstract][Full Text] [Related]
16. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy for recurrent spinal cord ependymona.
Chamberlain MC
Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
[TBL] [Abstract][Full Text] [Related]
18. [TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies].
Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Ota K; Ariyoshi H; Hattori T; Sugimachi K; Tsukagoshi S
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1253-61. PubMed ID: 9279344
[TBL] [Abstract][Full Text] [Related]
19. [A phase II study of oral VP-16 in primary lung cancer].
Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
[TBL] [Abstract][Full Text] [Related]
20. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]